Hawkeye Bio

Executive Summary

Hawkeye Bio is a private biotechnology company based in Cambridge, MA, developing AI-powered diagnostics for early cancer detection using a patented graphene biosensor platform. The platform measures enzymatic activity from non-invasive liquid biopsy samples (e.g., blood), enabling detection of malignancies at earlier, more treatable stages. The lead program, ProLung, targets lung cancer—the leading cause of cancer mortality—with a blood test designed to improve early-stage diagnosis. By combining graphene-based sensing with machine learning, Hawkeye aims to overcome sensitivity and specificity limitations of existing liquid biopsy approaches. Founded in 2020, the company has no disclosed funding, but its technology has the potential to fill a critical gap in cancer screening, particularly for high-risk populations.

Upcoming Catalysts (preview)

• Q3 2026Initiation of ProLung clinical validation study70% success
• Q4 2026Strategic partnership or licensing deal for graphene biosensor platform40% success
• TBDSeries A funding round announcement60% success